2020 ASCO Virtual Direct™ Highlights

 

Breast
16:18

2020 ASCO Virtual Direct™ Highlights

HER2+ EBC Clinical Data: Which Patients Should Be Considered for Neoadjuvant Systemic Therapy? How Should You Handle Residual Disease Post-NAC?

FEATURING Alvaro Moreno-Aspitia
  • 427 views
  • January 20, 2021
  • 2
12:33

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Adjuvant BC: NET Approaches for Stage II/III ER+ HER2- BC in Post-Menopausal Women, Chemotherapy De-Escalation Strategy & the Use of 70-Gene Signature MammaPrint

FEATURING Jennifer Crozier
  • 190 views
  • August 26, 2020
08:05

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Adjuvant HER2+ BC: Is T-DM1 + Pertuzumab Superior? Can Anthracycline-Free Regimes Be Equally Effective as Anthracycline-Containing Regimens?

FEATURING Jennifer Crozier
  • 256 views
  • August 26, 2020
12:03

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on De-Escalation in Early Stage HER2+ BC: Should All Patients Receive Neoadjuvant Chemotherapy Just Because They Have HER2+ Disease? Can 6 vs. 12 Months of Anti-HER2 Therapy Be Equally Effective?

FEATURING Alvaro Moreno-Aspitia
  • 242 views
  • August 26, 2020
17:35

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Metastatic HER2+ BC: Efficacy Evidence for Recently Approved Neratinib, Trastuzumab Deruxtecan & Tucatinib

FEATURING Alvaro Moreno-Aspitia
  • 146 views
  • August 26, 2020